elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38085327-368B263F-6F74-4320-B401-9DFF1011F13D
Q38085327-368B263F-6F74-4320-B401-9DFF1011F13D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38085327-368B263F-6F74-4320-B401-9DFF1011F13D
Emerging mitotic inhibitors for non-small cell carcinoma.
P2860
Q38085327-368B263F-6F74-4320-B401-9DFF1011F13D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38085327-368B263F-6F74-4320-B401-9DFF1011F13D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
95aa7780de2d80a5eb0577523f8b732ec7e25bfc
P2860
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.